Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience

Elboğa, Umut; Şahin, Ertan; Cayirli, Yusuf Burak; Okuyan, Merve; Aktaş, Gökmen; Şahin, Handan Haydaroğlu; Doğan, İlkay; Kuş, Tülay; Akkurd, D. M.; Cimen, Ufuk; Mumcu, Vuslat; Kılbaş, Benan; Çelen, Y. Zeki

doi:10.3390/tomography8010024

Cited by 18 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean of the median and mean uptake interval between radiotracer administration and scan acquisition for FAP and FDG radiotracer were 60 minutes (range, 10–60 minutes) 22–41,43–51 and 60 minutes (range, 40–60 minutes), 22,23,25–41,43,44,46–51 respectively. Eight studies did not report adverse events due to FAP radiotracer administration 23–25,29,32,43,49,50 (Supplement Table 1, Supplemental Digital Content, http://links.lww.com/CNM/A392).…”

Section: Methodsmentioning

confidence: 98%

“…The participants in all included studies received FAP and FDG PET/CT, 22–51 and the median interval between both examinations was 7 days (range, 1–14 days) 22–27,29–51 (Table 1).…”

Section: Methodsmentioning

confidence: 99%

“…In 20 of all included studies, the radiotracer activities administered intravenously to the patients are shown, depending on the body weight, which ranges from 2.59 to 5.55 MBq/kg for FDG and from 1.85 to 3.7 MBq/kg for FAP. 22,25,28,[30][31][32][33][35][36][37][38][39][40][41]44,[47][48][49][50][51] However, the mean of the median and mean radiotracer activities administered intravenously to the patients were 147.69 MBq (range, 111-259 MBq) for FAP in 9 of the included studies 23,24,26,27,29,34,43,45,46 and 271 MBq (range, 214-316 MBq) for FDG radiotracers in 6 of the studies 23,24,26,29,43,46 (Supplement Table 1, Supplemental Digital Content, http://links.lww.com/CNM/A392).…”

Section: Technical Aspects Of Pet/ct In the Included Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers

et al. 2022

View full text Add to dashboard Cite

Purpose: 18 F-FDG is the dominant radiotracer in oncology; however, it has limitations. Novel labeled fibroblast activation protein (FAP) radiotracers have been developed and published in several studies. Thus, this meta-analysis aimed to compare the detection rates (DRs) of FDG and FAP, based on previous studies from a systematic review. Methods: PubMed/MEDLINE and Cochrane library databases were used to perform a comprehensive and systematic search and are updated to April 30, 2022. The DR, relative risk, and the SUV max were calculated between the FAP and FDG tracers. Finally, the sensitivity, specificity, diagnostic odds ratio, and summary receiver operating characteristic curve of FAP and FDG were analyzed using gold and reference standards. Results: Thirty studies (1170 patients) were included in the meta-analysis. The relative risks of FAP DR for the primary tumor, recurrent tumor, lymph node metastasis, and distant metastasis were FDG 1.06-to 3.00-fold per patient and per lesion. For the primary tumor, FAP uptake was most intense in pancreatic cancer, followed by head and neck, cervical, colorectal, lung, gastric, and hepatocellular carcinoma, and was higher than FDG except for urological system cancer. The sensitivity (0.84-0.98), diagnostic odds ratio (19.36-358.47), and summary receiver operating characteristic curve (0.94-0.99) of FAP based on patient and lesion were better for primary tumors, LN metastasis, and distant metastasis than FDG. Conclusions: Fibroblast activation protein is an extremely potential radiotracer to replace most of the use of FDG in oncology. It is noteworthy that the FAP tracers for primary tumors had low specificity despite excellent sensitivity and had lower uptake than FDG in urological system cancer. In addition, the difference in detection between FAP and FDG for LN metastasis could not be certain in sarcoma.

show abstract

Section: Methodsmentioning

confidence: 98%

“…The participants in all included studies received FAP and FDG PET/CT, 22–51 and the median interval between both examinations was 7 days (range, 1–14 days) 22–27,29–51 (Table 1).…”

Section: Methodsmentioning

confidence: 99%

Section: Technical Aspects Of Pet/ct In the Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers

et al. 2022

View full text Add to dashboard Cite

show abstract

“…But, the increasing of background noise induced by reducing injection dose or scanning time was still hardly dispelled by Q.Clear reconstruction. 68 Ga-FAPI is an effective method for multiple tumor detection, even superior to 18 F-FDG for some common tumors [13,15]. It has been widely used in clinics as PET tracer for tumor detection.…”

Section: Discussionmentioning

confidence: 99%

“…One such example is 68 Ga-DOTA-FAPI-04 ( 68 Ga-FAPI), a Gallium-68 labeled broblast activation protein inhibitor. This PET radiotracer has recently been introduced to target cancer-associated broblasts and has been reported to detect many types of tumors [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Q.Clear Reconstruction for Reducing the Scanning Time for 68Gallium-DOTA-FAPI-04 PET/MR Imaging

Ruan

Qin

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: To determine whether Q.Clear positron emission tomography (PET) reconstruction may reduce tracer injection dose or shorten scanning time in 68Ga fibroblast activation protein inhibitor (FAPI) PET/magnetic resonance (MR) imaging. Methods: We retrospectively collected cases of 68Ga-FAPI whole-body imaging performed on integrated PET/MR. PET images were reconstructed using three different methods: Ordered Subset Expectation Maximization (OSEM) reconstruction with full scanning time, OSEM reconstruction with half scanning time, and Q.Clear reconstruction with half scanning time. We then measured standardized uptake values (SUVs) within and around lesions, alongside their volumes. We also evaluated image quality using lesion-to-background (L/B) ratio and signal to noise ratio (SNR). We then compared these metrics across the three reconstruction techniques using statistical methods. Results: Q.Clear reconstruction significantly increased SUVmax and SUVmean within lesions (by almost 40%) and reduced their volumes in comparison with OSEM reconstruction. Background SUVmax also increased significantly, while background SUVmean showed no difference. Average L/B values for Q.Clear reconstruction were only marginally higher than those from OSME reconstruction with half-time (full-time). SNR decreased significantly in Q.Clear reconstruction compared with OSEM reconstruction with full time (but not half time). Differences between Q.Clear and OSEM reconstructions in SUVmax and SUVmean values within lesions were significantly correlated with SUVs within lesions. Conclusions: Q.Clear reconstruction was useful for reducing PET injection dose or scanning time while maintaining the image quality. Q.Clear may affect PET quantification and it is necessary to establish diagnostic recommendations based on Q.Clear results for Q.Clear application.

show abstract

Clinical applications of fibroblast activation protein‐targeted theranostics in oncologic and nononcologic disease: Current status and future directions

Fu,

Guo,

Huang

et al. 2023

iRADIOLOGY

View full text Add to dashboard Cite

Quinoline‐based fibroblast activation protein (FAP) inhibitor (FAPI)‐based positron emission tomography (PET) imaging and radioligand therapy (RLT) are being investigated for use in a wide variety of diseases, and recent results have been promising. This review summarizes the current status of FAPI radiopharmaceuticals in PET imaging of malignant tumors and benign conditions and compares their diagnostic efficacy with 18F‐fluorodeoxyglucose. In addition, we summarize the previously published FAP‐targeted RLT data and discuss its current clinical use and future potential. Our qualitative summary can inform future research directions, medical guidelines, and optimal clinical decision‐making.

show abstract

Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience

Cited by 18 publications

References 31 publications

Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers

Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers

Q.Clear Reconstruction for Reducing the Scanning Time for 68Gallium-DOTA-FAPI-04 PET/MR Imaging

Clinical applications of fibroblast activation protein‐targeted theranostics in oncologic and nononcologic disease: Current status and future directions

Contact Info

Product

Resources

About